Athira Pharma Inc (ATHA)

[glenn1919]

ATHA..............................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783

[Awl416]

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

[Whalatane]

4:22 PM ET 02/14/2024
http://archive.fast-edgar.com/20240214/A3BEF62C8M22CZZ2222M2ZZZ5PKQZ2U2X262
Filed on: February 14, 2024

Baker Bros position
-------
Kiwi

[Whalatane]

“The new year is off to a strong start with the completion of enrollment in our Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease (AD), which we expect will enable topline data readout from the study in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
“The potential of fosgonimeton as a treatment for AD is supported by the independent, unblinded interim efficacy and futility analysis of the first 100 subjects in the Phase 2/3 LIFT-AD study and the results from the exploratory Phase 2 ACT-AD clinical trial, which showed potential congruent improvements in biomarkers of neurodegeneration, inflammation and Alzheimer’s disease protein pathologies as well as measures of cognition and function.”

“The totality of data shared to date strengthens our confidence in and supports the potential of our small molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The consistency of data from preclinical models across various neurodegenerative diseases and in Alzheimer’s patients suggests that our small molecule drug candidates may be neuroprotective, neurotrophic, procognitive and potentially disease-modifying. This includes our recently reported findings from the exploratory SHAPE Phase 2 clinical trial, the results of which showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.”

Kiwi

[Whalatane]

ATHA their P2/3 Alzheimer trial now fully enrolled.
Data in about 9 mths
They had an interim analysis run by an independent DMC ....Did not stop for futility . DMC said increase size of trial to power for statistically significant results ....so trial likely to show benefit .
Question is ....will the degree of benefit be clinically relevant .
-------------
Kiwi

[Whalatane]

The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi

[TrendTrade2016]

ATHA... what a bio beast running through the streets...watch the explosion on the horizon...

[TrendTrade2016]

What a day…what a stock!!!

[great_tree]

Any serious comments on their product vs. SAVA, CRTX, AVXL etc.?

[TrendTrade2016]

ATHA pushing hard into close

[TrendTrade2016]

ATHA bio beast is very mad. She wants to fill that gap

[TrendTrade2016]

ATHA is ready to move big next week, the best bio taking on Alzheimers

[TrendTrade2016]

ATHA starting to heat up..love this bio beast!!!

[TrendTrade2016]

ATHA another bio beast ready to beast

[maximumgriff]

Girt prices

[crudeoil24]

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.

[crudeoil24]

Athira Pharma started at buy with $36 stock price target at Stifel Nicolaus.